GPhA Says Slow FDA Approvals Contribute to Generic Drug Price Hikes

The Generic Pharmaceutical Association called for FDA action on more than 3,000 generic drug applications pending at the agency as part of a three-pronged approach that the generic drug lobby says could help stem recent price hikes of some generic drugs. Citing the lack of market competition as the culprit, GPhA also called on Congress to ease Risk Evaluation and Mitigation Strategies restrictions and FDA to move forward with the biosimilar pathway. GPhA President and CEO Ralph Neas released a...